Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EBIT (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of EBIT readings, the most recent being -$3.4 million for Q1 2026.

  • On a quarterly basis, EBIT fell 108.68% to -$3.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$35.3 million, a 163.65% decrease, with the full-year FY2025 number at $6.9 million, up 108.23% from a year prior.
  • EBIT hit -$3.4 million in Q1 2026 for Atara Biotherapeutics, up from -$31.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $38.8 million in Q1 2025 to a low of -$88.2 million in Q1 2022.
  • Median EBIT over the past 5 years was -$31.6 million (2025), compared with a mean of -$37.4 million.
  • The widest YoY moves for EBIT: up 224.18% in 2025, down 158.58% in 2025.
  • Atara Biotherapeutics' EBIT stood at -$75.5 million in 2022, then increased by 20.62% to -$60.0 million in 2023, then surged by 79.65% to -$12.2 million in 2024, then crashed by 158.58% to -$31.6 million in 2025, then surged by 89.32% to -$3.4 million in 2026.
  • The last three reported values for EBIT were -$3.4 million (Q1 2026), -$31.6 million (Q4 2025), and -$3.6 million (Q3 2025) per Business Quant data.